Landos BT-11 & LANCL2 Publications

The Safety, Tolerability, and Pharmacokinetics Profile of BT-11, an Oral, Gut-Restricted Lanthionine Synthetase C-Like 2 Agonist Investigational New Drug for Inflammatory Bowel Disease: A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Trial. Inflammatory Bowel Diseases. .
Validation of lanthionine synthetase C-like 2 (LANCL2) as a therapeutic target for systemic lupus erythematosus. The Journal of Immunology. .
Oral Treatment with BT-11 Ameliorates Inflammatory Bowel Disease by Enhancing Regulatory T Cell Responses in the Gut. The Journal of Immunology. .
Nonclinical Toxicology and Toxicokinetic Profile of an Oral Lanthionine Synthetase C-Like 2 (LANCL2) Agonist, BT-11. International Journal of Toxicology. .
Tu1739 – Translation of Immunometabolic Mechanisms of Bt-11 to Humans with Crohn’s Disease. AGA Journals. .
Activation of LANCL2 by BT-11 Ameliorates IBD by Supporting Regulatory T Cell Stability Through Immunometabolic Mechanisms. Inflammatory Bowel Diseases. .
Exploratory Studies With BT-11: A Proposed Orally Active Therapeutic for Crohn’s Disease. International Journal of Toxicology. .
An N,N-Bis(benzimidazolylpicolinoyl)piperazine (BT-11): A Novel Lanthionine Synthetase C-Like 2-Based Therapeutic for Inflammatory Bowel Disease. ACS Publications. .
Mo1691 Lanthionine Synthetase C-Like Receptor 2 (LANCL2): A Novel Therapeutic Target for Inflammatory Bowel Disease. AGA Journals . .

Landos NX-13 Publications